(±)19(20)-EDP Ethanolamide

An ω-3 endocannabinoid epoxide and CB receptor agonist

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
25ug

￥675.00

540.00

- +
50ug

￥1287.00

1030.00

- +
100ug

￥2450.00

1960.00

- +
500ug

￥10837.00

8670.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajci67552
CAS: 2123485-34-5
别名: 19,20-DHEA epoxide, 19,20-epoxy Docosapentaenoic Acid Ethanolamide, 19,20-EDP-EA, 19,20-EDP epoxide
分子式: C24H37NO3
分子量: 387.6
纯度: >98%
溶解度: DMF: 50 mg/ml,DMSO: 50 mg/ml,Ethanol: 50 mg/ml,Ethanol:PBS(pH 7.2) (1:1): 0.5 mg/ml
储存: Store at -20°C
库存: 现货

Background

(±)19(20)-EDP ethanolamide is an ω-3 endocannabinoid epoxide and cannabinoid (CB) receptor agonist (EC50s = 108 and 280 nM for CB1 and CB2, respectively). It is produced through direct epoxygenation of docosahexaenoyl ethanolamide by cytochrome P450 (CYP) epoxygenases. (±)19(20)-EDP ethanolamide (25 µM) reduces the viability of 143B metastatic osteosarcoma cells. It decreases the production of IL-6 and increases the production of IL-10 when used at concentrations ranging from 2.5 to 10 µM in BV-2 microglia stimulated by LPS and decreases LPS-induced cytotoxicity when used at concentrations ranging from 5 to 10 µM. It also decreases nitrite production when used at a concentration of 7.5 µM, an effect that can be partially reversed by the CB2 receptor antagonist AM630 and the PPARγ antagonist GW 9662 . (±)19(20)-EDP ethanolamide induces vasodilation of isolated preconstricted bovine coronary arteries (ED50 = 1.9 µM) and reduces tube formation by human microvascular endothelial cells (HMVECs) in a Matrigel? assay.